Is Jyong Biotech Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Jyong Biotech Ltd (MENS) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Jyong Biotech Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Jyong Biotech Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Jyong Biotech Ltd?

Muslim investors may consider investing in Jyong Biotech Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Jyong Biotech Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Jyong Biotech Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Jyong Biotech Ltd updated?

The Shariah compliance status of Jyong Biotech Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Jyong Biotech Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Jyong Biotech Ltd?

You can check the latest Shariah compliance status of Jyong Biotech Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

MENS Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: February 12, 2026

Report Source: 2025 2nd Quarter Report

Jyong Biotech Ltd. Stock Analysis MENS

United States Health Care Micro Cap Report: Q2, 2025

Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. The company is headquartered in Taipei City, New Taipei and currently employs 29 full-time employees. The company went IPO on 2025-06-17. The firm is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The firm has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.

Key Statistics of Jyong Biotech Ltd (MENS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$1.99$2.09

Today's Open

$2.09

Volume

55.20K

P/E Ratio (TTM)

52 Week Range

$1.43$67.00

Market Cap

157.38M

Avg. Volume

74.12K

Dividend Yield

Financial Metrics & Statements of Jyong Biotech Ltd (MENS)

FAQ's for Jyong Biotech Ltd (MENS)

According to Musaffa’s Shariah screening methodology, Jyong Biotech Ltd (MENS) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.